GLP-1 shows promise for patients with advanced fatty liver disease

MedicalXpress | juil. 17, 2026

Researchers at the University of California San Diego School of Medicine have reported results from a large international clinical trial showing that semaglutide, a medication in the GLP-1 class of drugs widely used to treat diabetes and obesity, may help reduce liver scarring in patients with advanced fatty liver disease, including those with early-stage cirrhosis.